


Rhythm Pharmaceuticals is a global biopharmaceutical company committed to transforming the lives of patients with rare neuroendocrine diseases.

Rhythm is advancing the clinical development program for setmelanotide, an MC4R agonist, as well as investigational MC4R agonists bivamelagon and RM-718. In addition, we are working to discover and advance new therapeutic options for patients with congenital hyperinsulinism (CHI).

**Rhythm clinical development pipeline:**



Complete Ongoing

\*Approved in Canada (6 years of age and older)

<sup>^</sup>Currently being studied as

<sup>†</sup>Setmelanotide is being studied in a proof-of-concept substudy of the Phase 3 TRANSCEND trial

For more information regarding clinical study opportunities and our ongoing research, please contact [clinicaltrials@rhythmtx.com](mailto:clinicaltrials@rhythmtx.com) or visit our website at <https://www.rhythmtx.com/>.

Abbreviations: LEPR, leptin receptor; MC4R, melanocortin-4 receptor; PCSK1, proprotein convertase subtilisin/kexin type 1; POMC, proopiomelanocortin.

© 2026 Rhythm Pharmaceuticals, Inc. All rights reserved. Rhythm and its logo are trademarks of Rhythm Pharmaceuticals, Inc. GL-SET-2000006 (13.06/2026)

For Scientific Exchange Purposes Only; Not for Promotion

